{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selumetinib+Sulfate", "query": { "intervention": "Selumetinib Sulfate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selumetinib+Sulfate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T13:01:21.565Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01750281", "title": "Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV" ], "interventions": [ { "name": "Selumetinib 75 mg", "type": "DRUG" }, { "name": "Docetaxel 75 mg/m2", "type": "DRUG" }, { "name": "Docetaxel 60 mg/m2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 212, "start_date": "2012-12-18", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2023-10-24", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 13, "location_summary": "Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01750281" }, { "nct_id": "NCT02768766", "title": "Intermittent Selumetinib for Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "Selumetinib, 100mg", "type": "DRUG" }, { "name": "Selumetinib, 125mg", "type": "DRUG" }, { "name": "Selumetinib, 150mg", "type": "DRUG" }, { "name": "Selumetinib, 175mg", "type": "DRUG" }, { "name": "Selumetinib, 200mg", "type": "DRUG" }, { "name": "Selumetinib, 225mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shaheer A. Khan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2017-02-28", "completion_date": "2020-09-18", "has_results": false, "last_update_posted_date": "2023-08-31", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 3, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02768766" }, { "nct_id": "NCT02093728", "title": "To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "selumetinib", "type": "DRUG" }, { "name": "itraconazole", "type": "DRUG" }, { "name": "fluconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 26, "start_date": "2014-04", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-06-30", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02093728" }, { "nct_id": "NCT01658943", "title": "Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Acinar Cell Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2012-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-03-09", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 534, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 350 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01658943" }, { "nct_id": "NCT01143402", "title": "Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Iris Melanoma", "Medium/Large Size Posterior Uveal Melanoma", "Ocular Melanoma With Extraocular Extension", "Recurrent Uveal Melanoma", "Small Size Posterior Uveal Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2010-06", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 32, "location_summary": "Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01143402" }, { "nct_id": "NCT00551070", "title": "Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Ovarian Serous Tumor", "Low Grade Ovarian Serous Adenocarcinoma", "Micropapillary Serous Carcinoma", "Primary Peritoneal Carcinoma", "Primary Peritoneal Low Grade Serous Adenocarcinoma", "Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 52, "start_date": "2007-12-17", "completion_date": "2020-11-13", "has_results": true, "last_update_posted_date": "2020-12-03", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 49, "location_summary": "Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 32 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551070" }, { "nct_id": "NCT01635023", "title": "A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "AZD6244 Dosing Period 1", "type": "DRUG" }, { "name": "AZD6244 Dosing Period 2", "type": "DRUG" }, { "name": "AZD6244 Dosing Period 3", "type": "DRUG" }, { "name": "AZD6244 Dosing Period 4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 27, "start_date": "2012-07", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2012-10-25", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01635023" }, { "nct_id": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Histiocytic Sarcoma", "Juvenile Xanthogranuloma", "Langerhans Cell Histiocytosis", "Malignant Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Soft Tissue Sarcoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Rhabdoid Tumor", "Stage III Osteosarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Osteosarcoma AJCC v7", "Stage IVB Osteosarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Samotolisib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tipifarnib", "type": "DRUG" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1377, "start_date": "2017-07-31", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155620" }, { "nct_id": "NCT02056392", "title": "To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "selumetinib placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 54, "start_date": "2014-03", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-11-09", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02056392" }, { "nct_id": "NCT02839720", "title": "Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Neurofibroma", "Neurofibromatosis Type 1", "Optic Nerve Glioma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-08-26", "completion_date": "2023-08-31", "has_results": true, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-09-24T13:01:21.565Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Bethesda, Maryland", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02839720" } ] }